// App-Quantinova.ai

3996 : KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110/p110 and HDAC6 with single-agent and combination activity

Researchers

Presenter

  • Stephen J. Shuttleworth

Principal Investigators

  • N/A

Medical Centers

  • Karus Therapeutics Ltd, Abingdon, Oxfordshire, United Kingdom.

Locations

  • United Kingdom

Companies

  • Karus Therapeutics L

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Oral cancer

  • Solid malignancies

  • Lymphomas

Biomarkers

  • Programmed death-ligand 1

  • Signal transducer and activator of transcription 3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved